The epidermal growth factor receptor (EGFR) is the prototypical member of a family of
membrane-associated intrinsic tyrosine kinase receptors, the ErbB family. EGFR is activated …

Hypertension and atherosclerosis are among the most common causes of mortality in both
developed and developing countries. Experimental animal models of hypertension and …

Although angiotensin II (AngII) is known to cause renal injury and fibrosis, the underlying
mechanisms remain poorly characterized. Here we show that hypertensive nephropathy …

The mechanisms by which angiotensin II (Ang II) promotes renal fibrosis remain
incompletely understood. Ang II both stimulates TGFβ signaling and activates the EGF …

Chronic kidney disease (CKD) is a major health and economic burden with a rising
incidence. During progression of CKD, the sustained release of proinflammatory and …

Mechanisms of progression of chronic renal diseases, a major healthcare burden, are poorly
understood. Angiotensin II (AngII), the major renin-angiotensin system effector, is known to …

Ang II, the primary effector pleiotropic hormone of the renin–angiotensin system (RAS)
cascade, mediates physiological control of blood pressure and electrolyte balance through …

Epidermal growth factor receptor (EGFR) activation impacts the physiology and
pathophysiology of the cardiovascular system, and inhibition of EGFR activity is emerging as …

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase. Its activation results
in beneficial or detrimental consequences, depending on the particular setting. Earlier …

Angiogenesis inhibitors that target the epidermal growth factor (EGF) receptor (EGFR) and
vascular endothelial growth factor (VEGF) constitute an important addition to the therapeutic …